Please use this identifier to cite or link to this item: http://hdl.handle.net/1822/32518

Full metadata record
DC FieldValueLanguage
dc.contributor.authorBaltazar, Fátimapor
dc.contributor.authorPinheiro, Célinepor
dc.contributor.authorSantos, Filipa Moraispor
dc.contributor.authorSilva, J. Azevedopor
dc.contributor.authorQueirós, Odíliapor
dc.contributor.authorPreto, Anapor
dc.contributor.authorCasal, Margaridapor
dc.date.accessioned2015-01-08T10:03:35Z-
dc.date.available2015-01-08T10:03:35Z-
dc.date.issued2014-
dc.identifier.issn0213-3911por
dc.identifier.urihttp://hdl.handle.net/1822/32518-
dc.descriptionProofspor
dc.description.abstractMonocarboxylate transporters (MCTs) belong to a family of transporters, encoded by the SLC16 gene family, which is presently composed by 14 members, but only MCT1 to 4 have been biochemically characterized. They have important functions in healthy tissues, being involved in the transmembrane transport of lactic acid and other monocarboxylic acids in human cells. One of the recently recognized hallmarks of cancer is altered metabolism, with high rates of glucose consumption and consequent lactate production. To maintain this metabolic phenotype, cancer cells upregulate a series of plasma membrane proteins, including MCTs. MCT1 and MCT4, in particular, play a dual role in the maintenance of the metabolic phenotype of tumour cells. On one hand, they facilitate the efflux of lactate and, on the other hand, they contribute to the preservation of the intracellular pH, by co-transporting a proton. Thus, MCTs are attractive targets in cancer therapy, especially in cancers with a hyper-glycolytic and acid-resistant phenotype. Recent evidence demonstrates that MCTs are involved in cancer cell uptake of chemotherapeutic agents, including 3-bromopyruvate. In this way MCTs can act as "Trojan horses", as their elevated expression in cancer cells can mediate the entry of this chemotherapeutic agent into the cells and selectively kill cancer cells. As a result, MCTs will be mediators of chemotherapeutic response, and their expression can be used as a molecular marker to predict response to chemotherapy.por
dc.language.isoengpor
dc.publisherF Hernandezpor
dc.rightsopenAccesspor
dc.subjectMonocarboxylate transporterspor
dc.subjectCancer therapypor
dc.subjectGlycolysispor
dc.subjectMolecular targetspor
dc.titleMonocarboxylate transporters as targets and mediators in cancer therapy responsepor
dc.typearticle-
dc.peerreviewedyespor
dc.relation.publisherversionhttp://www.hh.um.es/Forthcoming_original_articles.htmpor
sdum.publicationstatuspublishedpor
oaire.citationStartPage1511por
oaire.citationEndPage1524por
oaire.citationIssue12por
oaire.citationTitleHistology and Histopathologypor
oaire.citationVolume29por
dc.date.updated2014-12-11T18:27:49Z-
dc.identifier.pmid24921258por
dc.subject.wosScience & Technologypor
sdum.journalHistology and Histopathologypor
Appears in Collections:ICVS - Artigos em Revistas Internacionais com Referee

Files in This Item:
File Description SizeFormat 
baltazar f_histol histopathol 2014 proof.pdf2,6 MBAdobe PDFView/Open

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID